Cargando…

A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer

A randomised phase III trial of MVAC (methotrexate, vincristine, doxorubicin, cisplatin) vs gemcitabine and cisplatin (GC) (G 1000 mg m(−2) days 1, 8, and 15 plus C 70 mg m(−2) day 2, q 4 wks) indicated GC had similar efficacy and lower toxicity (JCO 2000). Significant haematologic toxicities in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hussain, S A, Stocken, D D, Riley, P, Palmer, D H, Peake, D R, Geh, J I, Spooner, D, James, N D
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409873/ https://www.ncbi.nlm.nih.gov/pubmed/15292922 http://dx.doi.org/10.1038/sj.bjc.6602112

Ejemplares similares

Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
por: Hussain, S A, et al.
Publicado: (2004)

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020)

A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer
por: Doval, D C, et al.
Publicado: (2004)

Successful treatment of metastatic bladder cancer by gemcitabine‐cisplatin re‐challenge after pembrolizumab
por: Arai, Takayuki, et al.
Publicado: (2021)

Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer
por: Millar, J, et al.
Publicado: (2005)

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
por: Narayan, Vivek, et al.
Publicado: (2016)

A phase II irinotecan–cisplatin combination in advanced pancreatic cancer
por: Markham, C, et al.
Publicado: (2003)

Phase I study of gemcitabine using a once every 2 weeks schedule.
por: Vermorken, J. B., et al.
Publicado: (1997)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancer
por: Massafra, Marco, et al.
Publicado: (2020)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
por: Kim, R D, et al.
Publicado: (2018)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
por: Galsky, Matthew D., et al.
Publicado: (2023)

A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid
por: Correale, P, et al.
Publicado: (2003)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Clinical course involving thrombocytosis and thrombocytopenia in a patient with bladder cancer treated with gemcitabine and cisplatin
por: Watanabe, Ayako, et al.
Publicado: (2021)

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
por: Yoshino, Hirofumi, et al.
Publicado: (2023)

Cisplatin/gemcitabine: Pancytopenia: case report
Publicado: (2021)

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
por: Nowak, A K, et al.
Publicado: (2002)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience
por: Pande, Shripad B., et al.
Publicado: (2012)

Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
por: Winer, Arthur, et al.
Publicado: (2021)

The effect of outpatient web-based online scheduling versus traditional staff scheduling systems on progression to surgery and no-show rates
por: Kachooei, Amir, et al.
Publicado: (2023)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
por: Ng, M, et al.
Publicado: (2005)

Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade
por: Goel, Sunny, et al.
Publicado: (2019)

Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer
por: Tomko, Andrea M., et al.
Publicado: (2022)

Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer
por: Rajan, Narayan, et al.
Publicado: (2014)

The impact of intra-fractional bladder filling on “Plan of the day” adaptive bladder radiotherapy
por: Krishnan, Aisling, et al.
Publicado: (2019)

Primary signet-ring cell carcinoma of the urinary bladder successfully managed with cisplatin and gemcitabine: a case report
por: El Ammari, Jalal Eddine, et al.
Publicado: (2013)

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Anticancer properties of cannabidiol and Δ(9)-tetrahydrocannabinol and synergistic effects with gemcitabine and cisplatin in bladder cancer cell lines
por: Whynot, Erin G., et al.
Publicado: (2023)

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling
por: Julka, P K, et al.
Publicado: (2008)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma
por: Pan, Minggui, et al.
Publicado: (2021)

Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update
por: Jin, Ting, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qobs30uq2s57cb7sdvhujkoqj9